- Home
- CNTB vs DRRX Comparison
CNTB vs DRRX Comparison
Compare CNTB & DRRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTB
- DRRX
- Stock Information
- Founded
- CNTB 2012
- DRRX 1998
- Country
- CNTB United States
- DRRX United States
- Employees
- CNTB N/A
- DRRX N/A
- Industry
- CNTB Biotechnology: Pharmaceutical Preparations
- DRRX Biotechnology: Pharmaceutical Preparations
- Sector
- CNTB Health Care
- DRRX Health Care
- Exchange
- CNTB Nasdaq
- DRRX Nasdaq
- Market Cap
- CNTB 54.4M
- DRRX 59.3M
- IPO Year
- CNTB 2021
- DRRX 2000
- Fundamental
- Price
- CNTB $1.81
- DRRX $1.88
- Analyst Decision
- CNTB Strong Buy
- DRRX Hold
- Analyst Count
- CNTB 2
- DRRX 1
- Target Price
- CNTB $7.50
- DRRX N/A
- AVG Volume (30 Days)
- CNTB 168.9K
- DRRX 3.0M
- Earning Date
- CNTB 08-13-2025
- DRRX 08-12-2025
- Dividend Yield
- CNTB N/A
- DRRX N/A
- EPS Growth
- CNTB N/A
- DRRX N/A
- EPS
- CNTB N/A
- DRRX N/A
- Revenue
- CNTB $1,965,000.00
- DRRX $1,657,000.00
- Revenue This Year
- CNTB N/A
- DRRX N/A
- Revenue Next Year
- CNTB N/A
- DRRX $673.00
- P/E Ratio
- CNTB N/A
- DRRX N/A
- Revenue Growth
- CNTB N/A
- DRRX N/A
- 52 Week Low
- CNTB $0.51
- DRRX $0.48
- 52 Week High
- CNTB $2.86
- DRRX $2.64
- Technical
- Relative Strength Index (RSI)
- CNTB 46.67
- DRRX 81.00
- Support Level
- CNTB $1.77
- DRRX $1.85
- Resistance Level
- CNTB $2.46
- DRRX $1.92
- Average True Range (ATR)
- CNTB 0.27
- DRRX 0.04
- MACD
- CNTB -0.07
- DRRX -0.02
- Stochastic Oscillator
- CNTB 5.80
- DRRX 60.00
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.
About DRRX DURECT Corporation
Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories, which include new chemical entities and proprietary pharmaceutical programs. The company's pipeline products consist of DUR-928, POSIMIR, and others. Geographically, the company operates in the United States, Europe, Japan, and other countries, of which key revenue is derived from Europe.